- Conditions
- Hypertension, Pulmonary
- Interventions
- Riociguat (BAY63-2521)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 5,942
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Irritable Bowel Syndrome
- Interventions
- TRYP-0082, Psychotherapy
- Drug · Behavioral
- Lead sponsor
- TRYP Therapeutics
- Industry
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
- Interventions
- Oral Encochleated Amphotericin B (CAMB), Fluconazole
- Drug
- Lead sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- BIO 300 Oral Suspension, Paclitaxel, Carboplatin, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Humanetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Milwaukee, Wisconsin
- Conditions
- Sialorrhea
- Interventions
- Incobotulinum Toxin A, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Crohn Disease
- Interventions
- BI 706321, Ustekinumab, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 15
- States / cities
- Northridge, California • Hialeah, Florida • Inverness, Florida + 12 more
- Conditions
- Smith-Lemli-Opitz Syndrome
- Interventions
- Cholesterol Suspension, CRH, Cholesterol
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- Not listed
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- AMN107
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 59
- States / cities
- Mobile, Alabama • Tucson, Arizona • Duarte, California + 48 more
- Conditions
- Colorectal Cancer
- Interventions
- Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Goodyear, Arizona • Springdale, Arkansas • Duarte, California + 15 more
- Conditions
- Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu's Arteritis, Henoch-Schoenlein Purpura, Behcet's Disease, CNS Vasculitis
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 707 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
- Interventions
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Chronic Kidney Disease, Chronic Periodontitis, Generalized, Moderate
- Interventions
- dental intervention
- Procedure
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Metastatic Breast Cancer
- Interventions
- Satraplatin
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Melanoma
- Interventions
- INXN-1001, INXN-3001
- Drug · Biological
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 8
- States / cities
- Santa Monica, California • Newark, Delaware • Savannah, Georgia + 5 more
- Conditions
- Head and Neck Cancer
- Interventions
- cisplatin, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 12
- States / cities
- Flemington, New Jersey • Mount Holly, New Jersey • Red Bank, New Jersey + 9 more
- Conditions
- Gout
- Interventions
- Febuxostat XR
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Cleft Palate, Pain, Postoperative Care, Perioperative Care, Children
- Interventions
- Methadone hydrochloride, Fentanyl/Hydromorphone
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Months to 4 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cystic Fibrosis
- Interventions
- Oral Glutathione, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 18
- States / cities
- Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 15 more
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 33 more
- Conditions
- Virus, HSV-1, Herpes Simplex 1, Herpes Simplex Labialis
- Interventions
- Purell Hand Sanitizer, Medical Grade Mineral Oil
- Drug
- Lead sponsor
- Leciel Bono
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Pocatello, Idaho • St. George, Utah
- Conditions
- Euvolemic Hyponatremia
- Interventions
- Lixivaptan, Placebo
- Drug
- Lead sponsor
- CardioKine Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 54 more
- Conditions
- Periodontitis, Infant, Premature
- Interventions
- Periodontal scaling and root planing, Scaling and root planing
- Procedure
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 823 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Head and Neck Cancer
- Interventions
- mutant p53 peptide pulsed dendritic cell vaccine, tetanus toxoid helper peptide, adjuvant therapy
- Biological · Procedure
- Lead sponsor
- Robert Ferris
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Meningitis, Cryptococcal, HIV Infections
- Interventions
- Fluconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Newark, New Jersey • Brooklyn, New York + 1 more